Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Mimedx (MDXG) over the last 14 years, with Q3 2025 value amounting to $2.9 million.

  • Mimedx's Change in Account Payables rose 37875.6% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 31488.33%. This contributed to the annual value of -$1.4 million for FY2024, which is 28007.66% down from last year.
  • According to the latest figures from Q3 2025, Mimedx's Change in Account Payables is $2.9 million, which was up 37875.6% from -$668000.0 recorded in Q2 2025.
  • Mimedx's 5-year Change in Account Payables high stood at $3.7 million for Q2 2021, and its period low was -$3.6 million during Q3 2021.
  • Its 5-year average for Change in Account Payables is $197789.5, with a median of $283000.0 in 2024.
  • In the last 5 years, Mimedx's Change in Account Payables surged by 687857.14% in 2023 and then crashed by 33068.43% in 2024.
  • Mimedx's Change in Account Payables (Quarter) stood at $669000.0 in 2021, then tumbled by 137.52% to -$251000.0 in 2022, then soared by 126.69% to $67000.0 in 2023, then soared by 964.18% to $713000.0 in 2024, then surged by 308.56% to $2.9 million in 2025.
  • Its Change in Account Payables was $2.9 million in Q3 2025, compared to -$668000.0 in Q2 2025 and $1.5 million in Q1 2025.